GT health — Wise Endocrine & Metabolic Care

Patient MessagingPatients

  • GLP-1 Medicines and Vision: The New FDA Warning

    GLP-1 Medicines and Vision: The New FDA Warning

    FDA’s new GLP-1 warning raises important questions about vision and medication safety. This article puts the rare risk of NAION in perspective, explains which symptoms need emergency evaluation, and distinguishes optic nerve injury from diabetic retinopathy. Learn how treatment benefits, eye history, and insulin combination pens shape individualized treatment decisions, with practical guidance for discussing concerns and your next scheduled dose with your care team.

    Categorized as , , , ,
  • Vabysmo vs Avastin: Wet AMD and Metabolic Health

    Vabysmo vs Avastin: Wet AMD and Metabolic Health

    Vabysmo and Avastin can help protect vision in wet age-related macular degeneration, but choosing treatment involves more than the eye. This article explores treatment intervals, medication costs, kidney health, blood pressure, and cardiovascular history. Learn how coordinated care with a retina specialist can connect effective eye treatment with the broader medical needs, practical limitations, and personal priorities that shape each patient’s daily life and independence.

    Categorized as ,
  • Oral GLP-1 Medications and How They Compare

    Oral GLP-1 Medications and How They Compare

    Oral GLP-1 medications offer an alternative to injections, but each option brings different benefits and practical demands. This article compares Rybelsus, Ozempic tablets, oral Wegovy, and Foundayo, explaining effectiveness, absorption, dosing routines, and digestive tolerability. Learn why larger oral doses do not automatically mean greater liver burden, and how personalized care connects medication choice with your diabetes, weight, overall cardiovascular health, and everyday treatment goals.

    Categorized as , , , ,
  • What Insulin Does Beyond Lowering Blood Sugar

    What Insulin Does Beyond Lowering Blood Sugar

    This article explains how insulin supports far more than blood sugar control. It connects energy storage, fat metabolism, muscle preservation, potassium balance, and brain signaling within one coordinated system. Learn how gut hormones help guide insulin release, why normal increases after meals matter, and how personalized metabolic care considers nutrition, strength, lipids, and individual treatment needs alongside glucose levels at every stage of ongoing treatment.

    Categorized as , ,
  • Why Insulin Resistance Care Must Be Personalized

    Why Insulin Resistance Care Must Be Personalized

    Insulin resistance can affect blood sugar, cholesterol, liver health, and blood pressure in different ways. This article explains why personalized care looks beyond weight or a single laboratory result. Learn how muscle strength, fat distribution, hormones, sleep, and daily routines shape a comprehensive treatment plan that addresses individual risks and supports lasting metabolic health and wellbeing in Montgomery County, Maryland, and through coordinated virtual care.

    Categorized as , ,
  • Heart Failure Is Becoming a Cardiometabolic Disease

    Heart Failure Is Becoming a Cardiometabolic Disease

    The 2026 ESC guideline changes how clinicians classify and treat heart failure. It removes the intermediate HFmrEF category, expands reduced-ejection-fraction heart failure below 50%, and recommends SGLT2 inhibitors and appropriate mineralocorticoid-receptor antagonists across the symptomatic spectrum. The guideline also brings obesity treatment, blood-pressure control, kidney protection, sleep evaluation, exercise, and muscle preservation into one integrated cardiometabolic framework for modern, individualized heart-failure care across diverse patients.

    Categorized as , , ,
  • New Study: Hybrid Obesity Care Beyond Weight Loss

    New Study: Hybrid Obesity Care Beyond Weight Loss

    A new randomized trial examined whether a 20-week hybrid lifestyle program could improve obesity treatment beyond usual medical care. Although it did not significantly increase the number of participants losing at least 5% of their weight, several cholesterol and liver markers improved. The findings show why obesity care should measure metabolic health, adherence, medication use, and sustainable daily habits alongside changes on the scale alone.

    Categorized as , , ,
  • Rethinking BMI: A Practical Way to Diagnose Obesity

    Rethinking BMI: A Practical Way to Diagnose Obesity

    Obesity diagnosis should begin with BMI, but it should not end there. Waist measurements reveal central adiposity, while organ health and daily function show whether excess body fat has become an active disease. This practical four-step framework connects body size, physiology, function, and treatment intensity. It also identifies hidden risks early, such as sarcopenic obesity, weight-promoting medications, sleep apnea, fatty liver disease, and declining mobility.

    Categorized as , , ,
  • Why a Lower HbA1c Is Not Always Better After 65

    Why a Lower HbA1c Is Not Always Better After 65

    A lower HbA1c can look reassuring, but in older adults it may hide recurrent hypoglycemia, unstable glucose, or excessive treatment. Individualized targets consider health, kidney function, cognition, nutrition, medications, and daily independence. This article explains why Time in Range matters, when insulin or sulfonylureas deserve reassessment, and how safer diabetes care balances long-term protection with immediate quality of life and preserves confidence in daily living.

    Categorized as , , ,
  • Beyond BMI: What a New Obesity Study Reveals

    Beyond BMI: What a New Obesity Study Reveals

    A new JAMA Network Open study asks whether obesity diagnosis needs several body measurements or whether BMI and waist circumference can provide enough practical information. The results show that BMI alone misses many people with excess body fat, while waist measurement adds meaningful insight. However, no number can replace a broader evaluation of metabolic health, organ function, muscle health, sleep, and daily function over time.

    Categorized as , , ,
  • Central Insulin Resistance: When the Brain Stops Listening

    Central Insulin Resistance: When the Brain Stops Listening

    Central insulin resistance develops when the brain responds weakly to insulin’s signals about appetite, energy balance, metabolism, and memory. It may accompany obesity, prediabetes, type 2 diabetes, fatty liver disease, poor sleep, and metabolic inflammation. Although no routine test can diagnose it, exercise, restorative sleep, thoughtful nutrition, weight management, and appropriate medication can improve the broader metabolic environment that shapes brain insulin signaling over time.

    Categorized as , , ,
  • Elevated Ferritin: Iron Overload or a Broader Signal?

    Elevated Ferritin: Iron Overload or a Broader Signal?

    An elevated ferritin level does not automatically mean the body contains too much iron. Ferritin can also rise with inflammation, fatty liver, metabolic dysfunction, kidney disease, infection, or alcohol use. The most meaningful interpretation combines ferritin with transferrin saturation, liver enzymes, blood counts, symptoms, and the pattern over time. This broader view helps identify the true cause and guides treatment toward the correct underlying problem.

    Categorized as , , ,